“Sputnik V vaccine, developed by the National Ministry of Health’s Epidemiology and Microbiology Research Center of the Russian Ministry of Health, has started to be tested on volunteers over 60 years old,” said Mikhail Murashko, Russian Minister of Health edit
Sputnik – The Russian Ministry of Health reported that the vaccine started to be applied to elderly volunteers, who are the demographics most likely to die if exposed to COVID-19.
Clinical trials of the Sputnik V vaccine have been started in Russia in volunteers over 60 years of age, Mikhail Murashko, health minister, told Sputnik.
“The Sputnik V vaccine, developed by the Gamaleya National Epidemiology and Microbiology Research Center, of the Russian Ministry of Health, has started to be tested on volunteers over 60,” said Murashko.
The Russian minister noted that it is very important that these patients obtain their vaccination parameters.
Previously, the Russian Ministry of Health issued a permit to conduct clinical trials of the Sputnik V vaccine on volunteers over 60 years old.
According to data released worldwide, the elderly are the group most vulnerable to death by COVID-19.
In August, the Russian Ministry of Health was the first in the world to register a vaccine against COVID-19, developed by the Gamaleya Center and called Sputnik V. The vaccine should be used in two doses, with an interval of three weeks.
Post-registration clinical trials of the coronavirus vaccine began in Moscow on 7 September, and the first participants were vaccinated on 9 September. In all, 40 thousand volunteers will participate in the study. Ten thousand of the participants will receive a placebo, needed to test the vaccine’s effectiveness.
This week, Russian President Vladimir Putin announced the registration of another Russian coronavirus vaccine, developed by the Vektor State Center for Virology and Biotechnology Research, called EpiVacCorona, whose post-registration trials will begin in the near future, including on people at risk outside the study, according to the Federal Service for the Defense of Consumer Rights and Human Welfare of Russia.
In addition, work is underway to create a live vaccine from the MP Chumakov Immunobiological Drug Research and Development Center of the Russian Academy of Sciences. A vaccine is also in development at the Federal University of Crimea Vernadsky.